Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge

Despite significant advances in targeted therapies against the hyperactivated BRAF(V600)/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cells resistant to trametinib, an agent broadly use...

Descripción completa

Detalles Bibliográficos
Autores principales: Koziej, Paulina, Kluszczynska, Katarzyna, Hartman, Mariusz L., Czyz, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178474/
https://www.ncbi.nlm.nih.gov/pubmed/37175614
http://dx.doi.org/10.3390/ijms24097891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178474/
https://www.ncbi.nlm.nih.gov/pubmed/37175614
http://dx.doi.org/10.3390/ijms24097891

Ejemplares similares